DRUG-ELUTING STENTS - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Drug-Eluting Stents in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of the World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain. The report profiles 39 companies including many key and niche players such as -

Abbott Vascular
Boston Scientific, Inc.
Biosensors International Pte Ltd.
Medtronic, Inc.
MIV Therapeutics Inc.


Click here to request a full list of companies covered in the report...

Code : MCP-1407
Price : $4500
Companies : 39
Pages : 282
Date : May 2012
Market Data Tables : 35

Complimentary Market Brief:


Request a Complimentary Copy of the Report Insights, Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS


 
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
   Recession Plummets Global DES Market.....II-11$100
   Major Issues and Trends.....II-2
Recession Hits Cardiovascular Device Makers.....II-2
Changing Fortunes in the Global DES Industry.....II-2
Global Market Recovers From Safety Issue Shambles.....II-2
1$100
   Competition Intensifies as New Products Make Way in to the Market.....II-3
Drug-Eluting Stents Transforming the Face of Interventional Cardiology Market.....II-3
1$100
   Table 1: Global Stents Market by Type (2011): Percentage Breakdown of Value Sales for Drug-Eluting Stents and Bare-Metal Stents (includes corresponding Graph/Chart).....II-4
Concerns over Adverse Effects Remain A Major Snag.....II-4
Potential Decline in Hospital Revenues.....II-4
Shift in Pricing Models to Increase Innovation Levels.....II-4
1$350
   Glaring Lack of Health-Related Initiatives the World Over.....II-5
Bioabsorbable Stents – Abbott Makes a Headstart with Absorb.....II-5
1$100
   A Brief Introduction to DES.....II-6
Suitable Patient Types for Drug-Eluting Stents.....II-6
J&J Exit from DES Market Improves Prospects for Competitors.....II-6
1$100
   Drug-Eluting Stents - Competitive Landscape.....II-71$100
   World Drug-Eluting Stents Market (2002-2012): DES Brands Launched by Major
  Manufacturers– Abbott Vascular Inc., Boston Scientific Corp., Cordis (Johnson &
    Johnson), Medtronic Inc., and Intersect Ent.....II-8
Boston Scientific Leads Global DES Market, Abbott Closes In.....II-8
1$100
   Table 2: World Drug Eluting Stents Market (2010): Market Share Breakdown of Value Sales by Leading Players - Boston Scientific, Abbott, Medtronic, and Others (includes corresponding Graph/Chart).....II-9
Xience and Promus Take the Lead.....II-9
Table 3: World Drug Eluting Stents Market (2010): Market Share Breakdown of Value Sales by Leading Brands - Xience V, Promus/Element, Taxus, Endeavor and Others (includes corresponding Graph/Chart).....II-9
1$350
   Major DES Drugs Available in the Market.....II-10
Sirolimus.....II-10
Paclitaxel.....II-10
Everolimus.....II-10
Zotarolimus.....II-10
Biolimus.....II-10
Other Treatments Available for Treating In-Stent Restenosis.....II-10
1$100
   Select Leading Drug-Eluting Stent Products in the Market.....II-11
XIENCE V (Abbott).....II-11
PROMUS® (Boston Scientific).....II-11
XIENCE PRIME (Abbott).....II-11
TAXUS® Liberté® Atom™ (Boston Scientific).....II-11
ENDEAVOR (Medtronics).....II-11
1$100
   TAXUS (Boston Scientific).....II-121$100
   Cardiovascular Diseases – A Brief Description.....II-13
Table 4: World Market for Cardiovascular Therapies (2011): Percentage Share Breakdown of Value Sales by Product Category-Drug-Eluting Stents, Cardiac Resynchronization Therapy, Cardiac Markers, Portable Automated External Defibrillators, and Angiogenesis/Gene Therapy (includes corresponding Graph/Chart).....II-13
1$350
   Coronary Heart Disease.....II-14
Traditional Methods of Treating Blockage of Coronary Arteries.....II-14
Percutaneous Transluminal Coronary Angioplasty (PTCA).....II-14
Coronary Artery Bypass Graft (CABG).....II-14
Restenosis.....II-14
Evolution of Coronary Stents as a Replacement for Traditional Methods.....II-14
1$100
   What are Coronary Stents?.....II-15
How is Coronary Stenting Performed – Procedure.....II-15
Risks and Problems Associated with Placing a Stent.....II-15
Restenosis Still Pervasive Even after the Use of Stents.....II-15
Market Analysis for Coronary Stents.....II-15
1$100
   By Region/Country.....II-16
Table 5: World Market for Coronary Stents (2011): Percentage Share Breakdown of Value Sales by Region/Country -US, Japan, Europe, Japan, and Rest of World (includes corresponding Graph/Chart).....II-16
In-Stent Restenosis – Outcome of Bare Metal Stents.....II-16
In-Stent Restenosis – Definition.....II-16
Causes of In-Stent Restenosis.....II-16
1$350
   Cost Evaluation of DES.....II-17
Initial Procedural Costs Remain High.....II-17
Table 6: Average Price Per DES Unit for the Period 2004-2005.....II-17

Table 7: Worldwide Average Stent Prices (2002-2005): Breakdown of Regions by Drug Eluting Stents and Bare Metal Stents.....II-17
1$350
   Follow-Up Costs Provide Relief.....II-18
Table 8: A Comparative Presentation of Long-Term Costs of DES and CABG.....II-18
Conversion of CABG Procedures to DES.....II-18
Impact of DES on Indirect Costs.....II-18
1$350
   Boston Completes European and Intercontinental Enrollment Phases.....II-19
Medtronic To Start Clinical Study.....II-19
Guidant Accomplishes Patient Enrollment.....II-19
Abbott Receives FDA Approval for Initiation of ZoMaxx Clinical Trials.....II-19
1$100
   Medtronic Commences Endeavor III Clinical Trial.....II-20
MIV Therapeutics Completes Drug-Eluting Stent Coating R&D Program.....II-20
Guidant Conducts First Implant as Part of Drug Eluting Stent Trial.....II-20
Medtronic’s Endeavor Drug Eluting Stent Shows Positive Results.....II-20
Cypher™ Coronary Stent Trials Show Restenosis Rates Decline by 5.1%.....II-20
1$100
   Boston Scientific Demonstrates Positive Results for Taxus IV Clinical Trial.....II-21
Medtronic Initiates Endeavor II Clinical Trials for Endeavor Drug Eluting
  Stent.....II-21
Guidant’s Clinical Trials for Coronary Stent Demonstrates Positive Results.....II-21
1$100
   MIV Commences Clinical Trials of HC Stent.....II-22
XTNT Voiced CUSTOM III Trial Program of NX™ DES System.....II-22
Dynatek Completes DES Coating Durability Trial.....II-22
STEALTH Trial.....II-22
1$100
   SIROCCO Trial.....II-23
Cook Trial.....II-23
ZoMAXX Trial.....II-23
Ravel Trial.....II-23
Sirius Trial.....II-23
C - Sirius Trial.....II-23
1$100
   E - Sirius Trial.....II-24
Taxus I through VI Clinical Trials.....II-24
Other Clinical Trials.....II-24
1$100
   Abbott Receives European Clearance for Bioabsorbable Stent.....II-25
NIMS Develops Am80 Drug Eluting Stent.....II-25
Cook Medical Unveils New CE Marked Zilver PTX Drug-Eluting Peripheral Stent.....II-25
1$100
   Medtronic Rolls Out Driver Sprint RX Coronary Stent System.....II-26
Boston Scientific Launches TAXUS Liberte DES In Japan.....II-26
1$100
   Medtronic Unveils Endeavor Sprint Drug-Eluting Stent in The US.....II-27
CeloNova Unveils CATANIA™ Stent System with NanoThin Polyzene®-F.....II-27
Abbott Launches Xience V Drug-Eluting Coronary Stent in Europe.....II-27
Boston Introduces Taxus(R) Express2(TM) in Japan.....II-27
1$100
   Cordis Brings Advanced Drug-Eluting Stent.....II-28
Sorin Unveils Enhanced Janus Flex in Europe.....II-28
EUREKA Develops Latest Generation of Drug- Eluting Stent.....II-28
1$100
   MIV Therapeutics Develops New Drug Eluting Coating Technology in Canada.....II-29
Medtronic to Launch Endeavor DES in Europe.....II-29
DISA Vascular (Pty) Ltd Introduces ChromoFlex in Europe.....II-29
1$100
   Boston Scientific Introduces Taxus Liberté Drug Eluting Stent in Europe.....II-30
Boston Scientific Introduces Innovative Drug-Eluting Stent, Taxus in the US
  Market.....II-30
1$100
   Boston Scientific Obtains CE Mark Approval for TAXUS Element™.....II-31
Biosensors Takes Over Cardiomind.....II-31
Tryton Medical Implants First Tryton® in Austria and Portugal.....II-31
Medtronic to Take Over Invatec.....II-31
1$100
   Abbott Obtains Approval for XIENCE V Stent System in Japan.....II-32
Boston Scientific Obtains Approval for Promus Stent In Japan.....II-32
Opto Circuits (India) Obtains CE Mark Approval for Taxcor Plus.....II-32
Abbott Obtains Approval for Additional Indications of Xience V and Xience
  Prime.....II-32
1$100
   Bayer MaterialScience to Acquire PolyBioMed.....II-33
Boston Scientific Obtains Health Canada Approval for PROMUS®.....II-33
Abbott Labs to Introduce XIENCE V Stent in China.....II-33
Abbott Obtains Approval for XIENCE V® from Health Canada.....II-33
1$100
   Boston Scientific Obtains FDA Approval for TAXUS® Liberte® Atom™ Stent.....II-34
Medtronic Obtains CE Mark Approval for Endeavor DES.....II-34
Biosensors International Group Receives CE Mark Approval for BioMatrix.....II-34
Medtronic Receives Approval for Endeavor Drug-eluting Stent in Japan.....II-34
1$100
   Boston Scientific Obtains Japanese Approval for TAXUS® Liberte® Atom™.....II-35
XTENT Receives CE Mark Approval for CUSTOM NX DES.....II-35
Maxcor Lifescience Inks Strategic Cooperation Agreement with Micell
  Technologies.....II-35
1$100
   Boston Scientific Snaps Up Labcoat.....II-361$100
   Medtronic Commences PROTECT Comparative Study in US.....II-37
B.Braun to Invest in its India based Operations.....II-37
Medtronic Secures TDP Approval for Endeavor Zotarolimus Eluting Coronary Stent.....II-37
1$100
   Medtronic Receives US FDA Approval for Endeavor Drug-Eluting Stent.....II-38
Novation and Medtronic Ink National Agreement.....II-38
MIV Therapeutics Acquires Biosync Scientific.....II-38
J & J Acquires Conor Medsystems.....II-38
FDA Approves Boston Scientifis’s Taxus Stent with Extended Shelf Life.....II-38
1$100
   Lombard Collaborates With S&N.....II-39
India Establishes Asia’s first Catheter and Stent Unit......II-39
Abbott Requests FDA Approval for Xience.....II-39
Brookwood and TTV Start Joint Venture.....II-39
SurModics Acquires Brookwood Pharmaceuticals, Inc.....II-39
1$100
   ARIAD Collaborates with ICON Medical.....II-40
Biosensors Acquires 50% Stake in JWMS.....II-40
Cordis’ Cypher Select™ Plus Receives Approval in Europe.....II-40
Boston Scientific Acquires Guidant for $27 Billion, Abbott Gets Guidant’s Vascular and
  Cardiac Therapies Businesses as Part of Deal.....II-40
1$100
   Conor COSTAR II Receives US FDA Approval.....II-41
Abbott Expands Vascular Sites in Ireland.....II-41
Medtronic’s Endeavor® Attains Reimbursement Approval in France.....II-41
SurModics Offers License for Hydrophilic Technology to Devax.....II-41
Conor obtains License for Novartis’ Pimecrolimus.....II-41
1$100
   Medtronics Makes Final PMA Submission for Endeavor.....II-42
Volcano Collaborates with CRF, Cardialysis and Stanford University.....II-42
Boston’s PROMUS Receives CE Mark Approval.....II-42
SurModics and X-Cell Inks Licensing Agreement.....II-42
Medtronic Receives Regulatory Approval for Endeavor (R).....II-42
1$100
   Medtronics’ Endeavor Obtains Chinese Regulatory Approval.....II-43
Biosensors Collaborates with JW Medical.....II-43
Biosensors and Weigao To Consolidate Joint Venture.....II-43
Biotronik Enters Multi-Drug Deal with Novartis.....II-43
1$100
   MIVT Enters Collaboration Deal with SMT.....II-44
SMT’s Infinnium Paclitaxel System Receives CE Mark.....II-44
Guidant’s Xience V Receives European Approval.....II-44
Medtronic Files Initial PMA Module TO US FDA.....II-44
Boston Scientific Receives European Approval for TAXUS(R).....II-44
Biosensors Attains US Patent Covering DES Technology.....II-44
1$100
   MediVas LLC and Estracure Inc Sign Agreement for Development of DES.....II-45
Relisys Medical of India Finalizes Deal with Germany Based Blue Membranes.....II-45
X-cell Medical Enrolls for Clinical Trial of ETHOS I Estradiol Eluting Stent......II-45
Biosensors International Group Receives CE Approval for First DES, Axxion.....II-45
1$100
   Boston Scientific Corp Receives CE Mark Approval for Marketing Larger Stent
  Sizes.....II-46
Medtronic Receives CE Mark Approval for Commercial Sale of Endeavor DES in
  Europe.....II-46
Biosensors International Opens New Interventional Cardiology Unit in Singapore.....II-46
Johnson & Johnson Recalls Cypher Drug-Eluting Stents.....II-46
Boston Scientific Buys Out Precision Vascular Systems.....II-46
1$100
   Implant Sciences and CardioTech International enter into Partnership with
  CorNova.....II-47
Avantec Vascular Corporation Signs Agreement with Novartis Pharma AG.....II-47
Guidant and Cordis Enter into Promotion Agreement.....II-47
Genvec Collaborates with Cordis.....II-47
1$100
   Cordis Receives Approval from Japanese Ministry of Health.....II-48
Boston Scientific Modifies Production of Taxus Drug-Eluting Stent.....II-48
Guidant Acquired CE Mark Approval for Multi-Link Bifurcation Stent System.....II-48
Boston Scientific Receives Reimbursement Approval from French Government.....II-48
Boston Scientific Withdraws Consortium of Drug-Coated Stents.....II-48
1$100
   Abbott Vascular (USA).....II-49
Boston Scientific, Inc. (USA).....II-49
Biosensors International Pte Ltd. (Singapore).....II-49
1$100
   Medtronic, Inc.(USA).....II-50
MIV Therapeutics, Inc. (Canada).....II-50
1$100
   Table 9: World Recent Past, Current and Future Analysis for Drug-Eluting Stents by Geographic Region – US, Japan, Europe and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-511$350
   Table 10: World Historic Review for Drug-Eluting Stents by Geographic Region – US, Japan, Europe and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-521$350
   Table 11: World 15-Year Perspective for Drug-Eluting Stents by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of the World Markets for Years 2003, 2011, & 2017 (includes corresponding Graph/Chart).....II-531$350
   A. Market Analysis.....III-1
Issues and Trends.....III-1
US Healthcare Ideology.....III-1
The Important Role of Medicaid in the US.....III-1
Boston Leads the DES Market.....III-1
1$75
   Table 12: US Drug Eluting Stents Market (2011): Market Share Breakdown by Leading Players – Boston Scientific, Abbott, Medtronic, and Johnson & Johnson (includes corresponding Graph/Chart).....III-2

Table 13: US Drug Eluting Stents Market (2011): Market Share Breakdown by Leading Brands – Xience V, Promus/Element, Taxus, Cypher, and Endeavor/Resolute (includes corresponding Graph/Chart).....III-2
Drug-Eluting Stents Launched in the US by Major Manufacturers (2003-2012).....III-2
1$200
   Select Leading DES Products in the Market.....III-3
Xience V – The Leader.....III-3
Taxus and Promus– The Other Leading DES.....III-3
Regulatory Environment.....III-3
FDA Framework.....III-3
FDA Approvals.....III-3
2$125
   B. Market Analytics.....III-5
Table 14: The US Recent Past, Current and Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-5
1$200
   Table 15: The US Historic Review for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-61$200
   A. Market Analysis.....III-7
Healthcare System in Japan.....III-7
Table 16: Japanese Market for Drug Eluting Stents (2005-2007): Market Share Breakdown of Sales Revenue by Major Players- Johnson & Johnson Boston Scientific, and Medtronic.....III-7
1$200
   B. Market Analytics.....III-8
Table 17: Japanese Recent Past, Current and Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-8
1$200
   Table 18: Japanese Historic Review for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-91$200
   A. Market Analysis.....III-10
Issues and Trends.....III-10
Reimbursement Woes Continue in Europe.....III-10
Reimbursement - A Major Hurdle in European Market Penetration of DES.....III-10
Slow Market Penetration of New Medical Devices in Europe.....III-10
Taxus – Leading the European Stent Market.....III-10
Healthcare System in Europe.....III-10
1$75
   B. Market Analytics.....III-11
Table 19: European Recent Past, Current and Future Analysis for Drug-Eluting Stents by Geographic Region – France, Germany, Italy, UK, Spain and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) (includes corresponding Graph/Chart).....III-11
1$200
   Table 20: European Historic Review for Drug-Eluting Stents by Geographic Region – France, Germany, Italy, UK, Spain and Rest of the Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-121$200
   Table 21: European 15-Year Perspective for Drug- Eluting Stents by Geographic Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain and Rest of Europe Markets for Years 2003, 2011 and 2017 (includes corresponding Graph/Chart).....III-131$200
   A. Market Analysis.....III-14
Healthcare System in France.....III-14
B. Market Analytics.....III-14
Table 22: French Recent Past, Current and Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-14
1$200
   Table 23: French Historic Review for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-151$200
   A. Market Analysis.....III-16
Healthcare Policies in Germany.....III-16
Lower Market Penetration of DES.....III-16
1$75
   B. Market Analytics.....III-17
Table 24: German Recent Past, Current and Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-17
1$200
   Table 25: German Historic Review for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-181$200
   A. Market Analysis.....III-19
Italian Healthcare System.....III-19
Local Healthcare Agencies.....III-19
National Health System in Italy.....III-19
1$75
   B. Market Analytics.....III-20
Table 26: Italian Recent Past, Current and Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-20
1$200
   Table 27: Italian Historic Review for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-211$200
   A. Market Analysis.....III-22
National Health System in the UK.....III-22
B. Market Analytics.....III-22
Table 28: The UK Recent Past, Current and Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-22
1$200
   Table 29: The UK Historic Review for Drug- Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-231$200
   A. Market Analysis.....III-24
Healthcare System in Spain.....III-24
B. Market Analytics.....III-24
Table 30: Spanish Recent Past, Current and Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-24
1$200
   Table 31: Spanish Historic Review for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-251$200
   Market Analytics.....III-26
Table 32: Rest of European Recent Past, Current and Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-26
1$200
   Table 33: Rest of European Historic Review for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-271$200
   A. Market Analysis.....III-28
Chinese Drug-Eluting Stents Market Witnesses Robust Growth.....III-28
B. Market Analytics.....III-28
Table 34: Rest of the World Recent Past, Current and Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-28
1$200
   Table 35: Rest of World Historic Review for Drug- Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-291$200
  
Total Companies Profiled: 39 (including Divisions/Subsidiaries - 46)

Region/Country Players

The United States 26 Canada 3 Japan 1 Europe 11 Germany 2 The United Kingdom 3 Italy 1 Rest of Europe 5 Asia-Pacific (Excluding Japan) 4 Africa 1
Click here to request a full table of contents and more details on this project.